• 1
    American Cancer Society. Cancer facts and figures—1991: ovarian cancer. New York: The Society, 1991: 13.
  • 2
    Tobias JS, Griffiths CT. Management of ovarian carcinoma: current concepts and future prospects. N Engl J Med 1976; 15: 81822.
  • 3
    McGarrity KA, Pettersson F, Ulfelder H, eds. Annual report on the results of treatment of gynecologic cancer, vol. 18: statement of results obtained in 1973 to 1975 inclusive. Stockholm: Radiumhemmet, 1982.
  • 4
    Malkasian GD Jr., Melton LJ III, O'Brien PC, Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 1984; 149: 27484.
  • 5
    Smith JP, Day TG. Review of ovarian cancer at the University of Texas Cancer Center, M. D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol 1979; 135: 98490.
  • 6
    Sigurdsson K, Alm P, Gullberg B. Prognostic factors in malignant epithelial ovarian tumors. Gynecol Oncol 1983; 15: 37080.
  • 7
    Day TG Jr., Gallager HS, Rutledge FN. Epithelial carcinoma of the ovary: prognostic importance of histologic grade. Natl Cancer Inst Monogr 1975; 42: 158.
  • 8
    Wharton JT, Edwards CL, Rutledge FN. Long-term survival after chemotherapy for advanced epithelial ovarian carcinoma. Am J Obstet Gynecol 1984; 148: 9971005.
  • 9
    Einhorn N, Nilsson B, Sjövall K. Factors influencing survival in carcinoma of the ovary: study from a well-defined Swedish population. Cancer 1985; 55: 201925.
  • 10
    Swenerton KD, Hislop TG, Spinelli J, LaRiche JC Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65: 26470.
  • 11
    Griffiths CT, Parker LM, Fuller AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979; 63: 23540.
  • 12
    Wharton JT, Herson J. Surgery for common epithelial tumors of the ovary. Cancer 1981; 48: 5829.
  • 13
    Heintz APM, van Ossterom A, Trimbos J, Schaberg A, VanDer Velde E, Nooy M. The treatment of advanced ovarian carcinoma: I. clinical variables associated with prognosis. Gynecol Oncol 1988; 30: 34758.
  • 14
    Redman J, Petroni G, Saigo P, Geller N, Hakes T. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 1986; 4: 51523.
  • 15
    Yancik R, Ries L, Yates J. Ovarian cancer in the elderly: an analysis of surveillance, epidemiology, and end results program data. Am J Obstet Gynecol 1986; 154: 63947.
  • 16
    Edwards CL, Herson J, Gershenson DM, Copeland L, Wharton JT. A prospective randomized clinical trial of melphalan and cisplatinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer. Gynecol Oncol 1983; 15: 26177.
  • 17
    Gershenson DM, Wharton JT, Copeland L, Stringer C, Edwards CL, Kavanagh J, et al. Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide. Gynecol Oncol 1989; 32: 33641.
  • 18
    SPSS Reference Guide. Chicago: SPSS Inc., 1990.
  • 19
    Berkson J, Gage RP. Survival for cancer patients following treatment. J Am Stat Assoc 1952; 47: 50115.
  • 20
    SAS Institute, Inc. SAS user's guide: basics, version 5 edition. Cary, NC: The Institute, 1985.